Zi‐Xun Yan

988 total citations
18 papers, 411 citations indexed

About

Zi‐Xun Yan is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Zi‐Xun Yan has authored 18 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Immunology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Zi‐Xun Yan's work include CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immune Cell Function and Interaction (5 papers). Zi‐Xun Yan is often cited by papers focused on CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immune Cell Function and Interaction (5 papers). Zi‐Xun Yan collaborates with scholars based in China, France and United Kingdom. Zi‐Xun Yan's co-authors include Yan Wang, Hua Yan, Junmin Li, Weili Zhao, Wenbin Xu, Jian‐Qing Mi, Li Wang, Weili Zhao, Pengpeng Xu and Shu Cheng and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Zi‐Xun Yan

15 papers receiving 406 citations

Peers

Zi‐Xun Yan

ONCOL

EPIDE

IMMUN

Longlong Xie China

Annalisa Roberti Spain

Wenjing Zhang China

Kayla McEnery United States

Liping Fan China

Sheng Han China

Nami McCarty United States

Carmen M. Anadon United States

Yisheng Wei China

Bettina Grötsch Germany

Longlong Xie China

Zi‐Xun Yan

264 ×1.1

145 ×1.0

ONCOL

119 ×1.2

76 ×1.0

EPIDE

94 ×1.5

IMMUN

Citations per year, relative to Zi‐Xun Yan Zi‐Xun Yan (= 1×) peers Longlong Xie

Countries citing papers authored by Zi‐Xun Yan

Since Specialization

Citations

This map shows the geographic impact of Zi‐Xun Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zi‐Xun Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zi‐Xun Yan more than expected).

Fields of papers citing papers by Zi‐Xun Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zi‐Xun Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zi‐Xun Yan. The network helps show where Zi‐Xun Yan may publish in the future.

Co-authorship network of co-authors of Zi‐Xun Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Zi‐Xun Yan. A scholar is included among the top collaborators of Zi‐Xun Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zi‐Xun Yan. Zi‐Xun Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Wang, Ronghui, Zhenhua Liu, Jipeng Yan, et al.. (2025). Identification of the histologic transformation of follicular lymphoma using super-resolution microcirculation imaging. Scientific Reports. 15(1). 16533–16533.

Cao, Weiguo, Wang Li, Lingshuang Sheng, et al.. (2025). Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study. Clinical and Translational Medicine. 15(4). e70310–e70310. 1 indexed citations

Yan, Zi‐Xun, Q. L. Niu, Wen Wu, et al.. (2024). Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma. Nature Communications. 15(1). 5183–5183. 18 indexed citations

Yan, Zi‐Xun, Lingshuang Sheng, Li Wang, et al.. (2024). A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7027–7027. 2 indexed citations

Yan, Zi‐Xun, Li Li, Di Fu, et al.. (2023). Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Frontiers of Medicine. 17(4). 699–713. 14 indexed citations

Sheng, Lingshuang, Yilun Zhang, Qi Song, et al.. (2023). Concurrent remission of lymphoma and Sjögren’s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report. Frontiers in Immunology. 14. 1298815–1298815. 26 indexed citations

Yan, Zi‐Xun, Dehui Zou, Yuhua Li, et al.. (2023). Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population. Blood. 142(Supplement 1). 6928–6928.

Li, Li, Qing Li, Zi‐Xun Yan, et al.. (2022). Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Scientific Reports. 12(1). 12506–12506. 38 indexed citations

Yan, Zi‐Xun, Yongxian Hu, Lingshuang Sheng, et al.. (2022). Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) as second-line therapy for primary refractory Chinese patients with large B-cell lymphoma (LBCL): Results from an open-label, multicenter, single-arm phase I study.. Journal of Clinical Oncology. 40(16_suppl). e19509–e19509.

10.

Yan, Zi‐Xun, Jingjing Wen, Di Fu, et al.. (2021). CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis. Molecular Cancer. 20(1). 153–153. 24 indexed citations

11.

Zhao, Ping, Mengyuan Ji, Ying Fang, et al.. (2021). A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes. Cell Death and Disease. 12(4). 321–321. 15 indexed citations

12.

Cheng, Shu, Xin Wang, Jianda Hu, et al.. (2020). CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. Genome Medicine. 12(1). 41–41. 10 indexed citations

13.

Cheng, Shu, Xin Wang, Jianda Hu, et al.. (2019). CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial. Blood. 134(Supplement_1). 1556–1556. 3 indexed citations

14.

Yan, Zi‐Xun, Wen Wang, Zhong Zheng, et al.. (2018). Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. Blood. 132(Supplement 1). 4187–4187. 6 indexed citations

15.

Wang, Yan, Wenbin Xu, Zi‐Xun Yan, et al.. (2018). Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways. Journal of Experimental & Clinical Cancer Research. 37(1). 63–63. 199 indexed citations

16.

Xu, Pengpeng, Ying Fang, Qi Song, et al.. (2017). JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide. Scientific Reports. 7(1). 7433–7433. 22 indexed citations

17.

Yan, Zi‐Xun, Zhong Zheng, Wen Xue, et al.. (2015). MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance. BioMed Research International. 2015. 1–10. 28 indexed citations

18.

Huang, Jianqing, et al.. (2015). [Clinical and prognostic analysis of 21 cases of primary breast lymphoma].. PubMed. 36(4). 277–81. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact